Aspeya
Thomas Blaettler currently serves as the Chief Medical Officer and Head of Global Clinical Development at Vectura Fertin Pharma since May 2023. Previously, Thomas held the Chief Medical Officer position at Coave Therapeutics from November 2021 to April 2023 and at Orphazyme A/S from November 2016 to October 2021. Thomas's extensive experience at Roche from 2009 to 2016 included roles such as PD Group Medical Director in Neuroscience and leading the Olesoxime Global Development program. Earlier positions include Medical Director at Bristol-Myers Squibb and Translational Medicine Expert II at Novartis. Thomas earned an MD from the University of Zurich from 1988 to 1994.
This person is not in any teams
This person is not in any offices
Aspeya
We are on a journey to empower healthier lifestyles and target specific unmet needs. We do this by being innovative, optimizing formulas, and applying rigorous scientific standards. This involves harnessing deep insight and scientific substantiation to reimagine how ingredients can be used, and working towards the development and commercialization of a pipeline of wellness and healthcare products and brands. We are applying our expertise to innovate in four areas of focus: Consumer health, cannabinoids, inhaled therapeutics, and nicotine replacement therapy. Our people are open-minded thinkers, leading-edge scientists, and knowledgeable innovators. Want to join our team? Visit our careers site to search for opportunities: careers.aspeya.com